Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models
5 affiliations
- 12Chonnam National University Hwasun Hospital, Hwasun-gun, Jellanamdo, Republic of Korea
- 2Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- 35Kongju National University, Yesan, Korea, Republic of Korea
- 41Vaxcell-bio CO., LTD., Hwasun-gun, Jellanamdo, Republic of Korea
- 5Vaxcell-bio CO., LTD., Hwasun-gun, Jeollanamdo, Republic of Korea
Related
- An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.
- Pharmacokinetic and dosimetric evaluation of [177Lu]Lu-FAPI for stromal-targeted radionuclide therapy in triple-negative breast cancer: a preclinical biodistribution and dosimetry study
- 577 Biopsy-associated tumor regression in late relapsed DLBCL after tandem CD20-CD19 CAR-T cell therapy
- Adjunctive Cerebrolysin therapy following mechanical thrombectomy for tandem right internal carotid artery and middle cerebral artery occlusion with residual post-procedural perfusion deficit: a case report
- Multimodal Effects of CD40L Blockade in Multiple Sclerosis: Insights from Preclinical and Clinical Studies
BibTeX
@article{lee2026preclinical,
title = {{200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models}},
author = {Je-Jung Lee and Jiwon Yang and Sang-ki Kim and Minwoo Baek and Sechan Oh and Yeo Jin Lim},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0200},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0200},
note = {CC BY},
}
RIS
TY - JOUR
TI - 200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models
AU - Je-Jung Lee
AU - Jiwon Yang
AU - Sang-ki Kim
AU - Minwoo Baek
AU - Sechan Oh
AU - Yeo Jin Lim
PY - 2026
DA - 2026/11/07
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0200
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0200
SN - 2051-1426
ER -